
Title:
Naproxen
Text:
Nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, menstrual cramps, inflammatory diseases such as rheumatoid arthritis, gout, and fever
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}"Antalgin" redirects here. Not to be confused with Analgin.


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}NaproxenClinical dataPronunciation/nəˈprɒksən/ Trade namesAleve, Naprosyn, others[1][2]AHFS/Drugs.comMonographMedlinePlusa681029License data
EU EMA: by INN
US DailyMed: Naproxen
US FDA: Naproxen
Pregnancycategory
AU: C[3]

Routes ofadministrationBy mouthATC codeG02CC02 (WHO) M01AE02 (WHO), M02AA12 (WHO), M01AE56 (WHO), M01AE52 (WHO)Legal statusLegal status
AU: S2 (Pharmacy medicine) when in preparations that contain no more than 15 days' supply. Otherwise it is Schedule 4 (Prescription only).[4]
CA: OTC 
UK: P (for menstrual use), otherwise POM 
US: OTC / Rx-only
Pharmacokinetic dataBioavailability95% (by mouth)Protein binding99%MetabolismLiver (to 6-desmethylnaproxen)Elimination half-life12–17 hours (adults)[5]ExcretionKidneyIdentifiers
IUPAC name
(+)-(S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid
CAS Number22204-53-1 YPubChem CID156391DrugBankDB00788 YChemSpider137720 YUNII57Y76R9ATQKEGGD00118 Yas salt: D00970 YChEBICHEBI:7476 YChEMBLChEMBL154 YPDB ligandNPX (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID4040686 ECHA InfoCard100.040.747 Chemical and physical dataFormulaC14H14O3Molar mass230.263 g·mol−13D model (JSmol)Interactive imageMelting point152–154 °C (306–309 °F)
SMILES
COc1cc2ccc(cc2cc1)[C@H](C)C(=O)O

InChI
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1 YKey:CMWTZPSULFXXJA-VIFPVBQESA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Naproxen, sold under the brand name Aleve or Apronax   among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, menstrual cramps, inflammatory diseases such as rheumatoid arthritis, gout and fever.[6] It is taken orally.[6] It is available in immediate and delayed release formulations.[6] Onset of effects is within an hour and last for up to twelve hours.[6]
Common side effects include dizziness, headache, bruising, allergic reactions, heartburn, and stomach pain.[6] Severe side effects include an increased risk of heart disease, stroke, gastrointestinal bleeding, and stomach ulcers.[6] The heart disease risk may be lower than with other NSAIDs.[6] It is not recommended in people with kidney problems.[6] Use is not recommended in the third trimester of pregnancy.[6]
Naproxen is a nonselective COX inhibitor.[6] As an NSAID, naproxen appears to exert its anti-inflammatory action by reducing the production of inflammatory mediators called prostaglandins.[7] It is metabolized by the liver to inactive metabolites.[6]
Naproxen was patented in 1967, and approved for medical use in the United States in 1976.[8][6][9] It is available over the counter and as a generic medication.[6][10] In 2019, it was the 61st most commonly prescribed medication in the United States, with more than 11 million prescriptions.[11][12]

Contents

1 Medical uses

1.1 Available formulations
1.2 Pregnancy and lactation


2 Adverse effects

2.1 Gastrointestinal
2.2 Cardiovascular


3 Interactions

3.1 Drug–drug interactions


4 Pharmacology

4.1 Mechanism of action
4.2 Pharmacokinetics
4.3 Pharmacogenetics


5 Chemistry

5.1 Synthesis


6 Society and culture

6.1 Brand names
6.2 Access restrictions


7 Research
8 Veterinary use

8.1 Horses


9 References
10 External links



Medical uses[edit]
Naproxen's medical uses are related to its mechanism of action as an anti-inflammatory compound.[8] Naproxen is used to treat a variety of inflammatory conditions and symptoms that are due to excessive inflammation, such as pain and fever (naproxen has fever-reducing, or antipyretic, properties in addition to its anti-inflammatory activity).[8] Inflammatory sources of pain that may respond to naproxen's anti-inflammatory activity are conditions such as migraine, osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, and bursitis.[1]
Naproxen sodium is used as a "bridge therapy" in medication-overuse headache to slowly take patients off other medications.[13]

Available formulations[edit]
Naproxen sodium is available as both an immediate release and as an extended release tablet. The extended release formulations (sometimes called "sustained release," or "enteric coated") take longer to take effect than the immediate release formulations, and therefore are less useful when immediate pain relief is desired. Extended release formulations are more useful for the treatment of chronic, or long-lasting, conditions, in which long-term pain relief is desirable.[14]


		
			
			
250 mg tablet of naproxen

			
		
		
			
			
220 mg tablet of naproxen sodium. Imprint L490 (upside-down). Round, light blue tablet.[14]

			
		
		
			
			
Naproxen extended release 500 mg, back and front.

			
		

Pregnancy and lactation[edit]
Small amounts of naproxen are excreted in breast milk.[1] However, adverse effects are uncommon in infants breastfed from mother taking naproxen.[15]

Adverse effects[edit]
Common adverse effects include dizziness, drowsiness, headache, rash, bruising, and gastrointestinal upset.[8][1] Heavy use is associated with increased risk of end-stage renal disease and kidney failure.[8][16] Naproxen may cause muscle cramps in the legs in 3% of people.[17]
In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[18][19] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[18][19]

Gastrointestinal[edit]
As with other non-COX-2 selective NSAIDs, naproxen can cause gastrointestinal problems, such as heartburn, constipation, diarrhea, ulcers and stomach bleeding.[20] Naproxen should be taken orally with food to decrease the risk of gastrointestinal side effects.[citation needed] Persons with a history of ulcers or inflammatory bowel disease should consult a doctor before taking naproxen.[citation needed] In U.S. markets, naproxen is sold with boxed warnings about the risk of gastrointestinal ulceration or bleeding.[1] Naproxen poses an intermediate risk of stomach ulcers compared with ibuprofen, which is low-risk, and indometacin, which is high-risk.[21] To reduce stomach ulceration risk, it is often combined with a proton-pump inhibitor (a medication that reduces stomach acid production) during long-term treatment of those with pre-existing stomach ulcers or a history of developing stomach ulcers while on NSAIDs.[22][23]

Cardiovascular[edit]
COX-2 selective and nonselective NSAIDs have been linked to increases in the number of serious and potentially fatal cardiovascular events, such as myocardial infarctions and strokes.[24] Naproxen is, however, associated with the smallest overall cardiovascular risks.[25][26] Cardiovascular risk must be considered when prescribing any nonsteroidal anti-inflammatory drug. The drug had roughly 50% of the associated risk of stroke compared with ibuprofen, and was also associated with a reduced number of myocardial infarctions compared with control groups.[25]
A study found that high-dose naproxen induced near-complete suppression of platelet thromboxane throughout the dosing interval and appeared not to increase cardiovascular disease (CVD) risk, whereas other non-aspirin high-dose NSAID regimens had only transient effects on platelet COX-1 and were associated with a small but definite vascular hazard. Conversely, naproxen was associated with higher rates of upper gastrointestinal bleeding complications compared with other NSAIDs.[26]

Interactions[edit]
Drug–drug interactions[edit]
Naproxen may interact with antidepressants, lithium, methotrexate, probenecid, warfarin and other blood thinners, heart or blood pressure medications, including diuretics, or steroid medicines such as prednisone.[1]
NSAIDs such as naproxen may interfere with and reduce the efficacy of SSRI antidepressants,[27] as well as increase the risk of bleeding greater than the individual bleeding risk of either class of agent, when taken together.[28] Naproxen is not contraindicated in the presence of SSRIs, though concomitant use of the medications should be done with caution.[28]Alcohol consumption increases the risk of gastrointestinal bleeding when combined with NSAIDs like naproxen in a dose-dependent manner (that is, the higher the dose of naproxen, the higher the risk of bleeding).[29] The risk is highest for people who are heavy drinkers.[29]

Pharmacology[edit]
Mechanism of action[edit]
Naproxen works by reversibly inhibiting both the COX-1 and COX-2 enzymes as a non-selective coxib.[30][31][32][33][34] This results in the inhibition of prostaglandin synthesis. Prostaglandins act as signaling molecules in the body, inducing inflammation. Thus, by inhibiting COX-1/2, naproxen induces an anti-inflammatory effect.

Pharmacokinetics[edit]
Naproxen is a minor substrate of CYP1A2 and CYP2C9. It is extensively metabolized in the liver to 6-O-desmethylnaproxen, and both the parent drug and the desmethyl metabolite undergo further metabolism to their respective acylglucuronide conjugated metabolites.[35] An analysis of two clinical trials shows that naproxen's time to peak plasma concentration occurs between 2–4 hours after oral administration, though naproxen sodium reaches peak plasma concentrations within 1–2 hours.[5][clarification needed]

Pharmacogenetics[edit]
The pharmacogenetics of naproxen has been studied in an effort to better understand its adverse effects.[36] In 1998, a small pharmacokinetic (PK) study failed to show that differences in a patient's ability to clear naproxen from the body could account for differences in a patient's risk of experiencing the adverse effect of a serious gastrointestinal bleed while taking naproxen.[36] However, the study failed to account for differences in the activity of CYP2C9, a drug-metabolizing enzyme that is necessary for clearing naproxen.[36] Studies on the relationship between CYP2C9 genotype and NSAID-induced gastrointestinal bleeds have shown that genetic variants in CYP2C9 that reduce the clearance of major CYP2C9 substrates (like naproxen) increase the risk of NSAID-induced gastrointestinal bleeds, especially for homozygous defective variants.[36]
As of October 2017[update], there were no recommendations for routine CYP2C9 testing for naproxen.[37][clarification needed]

Chemistry[edit]
Naproxen is a member of the 2-arylpropionic acid (profen) family of NSAIDs.[38] The free acid is an odorless, white to off-white crystalline substance.[citation needed] It is lipid-soluble and practically insoluble in water. It has a melting point of 152–155 °C.[citation needed]

Synthesis[edit]
Naproxen has been industrially produced by Syntex starting from 2-naphthol as follows:[39]

  
Society and culture[edit]
Brand names[edit]
Naproxen and naproxen sodium are marketed under various brand names, including Accord, Aleve, Anaprox, Antalgin, Apranax, Feminax Ultra, Flanax, Inza, Maxidol, Nalgesin, Naposin, Naprelan, Naprogesic, Naprosyn, Narocin, Pronaxen, Proxen, and Soproxen.[2] It is also available as the combination naproxen/esomeprazole magnesium in delayed release tablets under the brand name Vimovo.[2][40]

Access restrictions[edit]
Syntex first marketed naproxen in 1976, as the prescription drug Naprosyn. They first marketed naproxen sodium under the brand name Anaprox in 1980. It remains a prescription-only drug in much of the world.[citation needed] In the United States, the Food and Drug Administration (FDA) approved it as an over-the-counter (OTC) drug in 1994. OTC preparations of naproxen in the U.S. are mainly marketed by Bayer HealthCare under the brand name Aleve and generic store brand formulations in 220 mg tablets.[41] In Australia, packets of 275 mg tablets of naproxen sodium are Schedule 2 pharmacy medicines, with a maximum daily dose of five tablets or 1375 mg. In the United Kingdom, 250 mg tablets of naproxen were approved for OTC sale under the brand name Feminax Ultra in 2008, for the treatment of primary dysmenorrhoea in women aged 15 to 50.[42] In the Netherlands, 220 mg and 275 mg tablets are available OTC in drugstores, 550 mg is OTC only at pharmacies. Aleve became available over the counter in some provinces in Canada[43] on 14 July 2009, but not British Columbia, Quebec or Newfoundland and Labrador;[44] it subsequently became available OTC in British Columbia in January 2010.[45]

Research[edit]
Naproxen may have antiviral activity against influenza. In laboratory research, it blocks the RNA-binding groove of the nucleoprotein of the virus, preventing formation of the ribonucleoprotein complex—thus taking the viral nucleoproteins out of circulation.[46]

Veterinary use[edit]
Horses[edit]
Naproxen is given by mouth to horses at a dose of 10 mg/kg, and has shown to have a wide safety margin (no toxicity when given at three times the recommended dose for 42 days).[47] It is more effective for myositis than the commonly used NSAID phenylbutazone, and has shown especially good results for treatment of equine exertional rhabdomyolysis,[48] a disease of muscle breakdown; it is less commonly used for musculoskeletal disease.[medical citation needed]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c d e f .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Naproxen". Drugs.com. 2017. Retrieved 7 February 2017.

^ Jump up to: a b c "Naproxen international". Drugs.com. 7 December 2020. Retrieved 3 January 2021.

^ "Naproxen Use During Pregnancy". Drugs.com. 13 August 2019. Retrieved 27 December 2019.

^ Gill, A, ed. (July 2013). Standard for the Uniform Scheduling of Medicines and Poisons No. 4 (PDF). The Poisons Standard 2013. Therapeutic Goods Administration. ISBN 978-1-74241-895-7.

^ Jump up to: a b Angiolillo DJ, Weisman SM (April 2017). "Clinical Pharmacology and Cardiovascular Safety of Naproxen". American Journal of Cardiovascular Drugs. 17 (2): 97–107. doi:10.1007/s40256-016-0200-5. PMC 5340840. PMID 27826802.

^ Jump up to: a b c d e f g h i j k l m "Naproxen Monograph for Professionals". Drugs.com. AHFS. Retrieved 19 December 2018.

^ McEvoy GK (2000). AHFS Drug Information, 2000. American Society of Health-System Pharmacists. p. 1854. ISBN 9781585280049.

^ Jump up to: a b c d e "Naprosyn- naproxen tablet EC-Naprosyn- naproxen tablet, delayed release Anaprox DS- naproxen sodium tablet". DailyMed. 1 July 2019. Retrieved 27 December 2019.

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495.

^ "Medicines A to Z - Naproxen". NHS. National Health Service. 24 October 2018. Retrieved 11 March 2020.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Naproxen - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ Garza I, Schwedt TJ (2010). "Diagnosis and Management of Chronic Daily Headache". Seminars in Neurology. WebMD LLC. 30 (2): 154–66. doi:10.1055/s-0030-1249224. PMID 20352585. Retrieved 17 May 2017.

^ Jump up to: a b "L490 (Naproxen 220 mg)". drugs.com. Drugs.com. Retrieved 17 May 2017.

^ "LACTMED: NAPROXEN". TOXNET. NIH. Retrieved 21 July 2017.

^ Perneger TV, Whelton PK, Klag MJ (December 1994). "Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs". The New England Journal of Medicine. 331 (25): 1675–9. doi:10.1056/nejm199412223312502. PMID 7969358.

^ Allen RE, Kirby KA (August 2012). "Nocturnal leg cramps". American Family Physician. 86 (4): 350–5. PMID 22963024.

^ Jump up to: a b "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020.  This article incorporates text from this source, which is in the public domain.

^ Jump up to: a b "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020.  This article incorporates text from this source, which is in the public domain.

^ "Naproxen". PubMed Health. 1 September 2008. Archived from the original on 22 July 2010.

^ Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M,  et al. (July 2004). "Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach". Annals of the Rheumatic Diseases. 63 (7): 759–66. doi:10.1136/ard.2003.015925. PMC 1755051. PMID 15194568.

^ Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

^ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. pp. 665, 673. ISBN 978-0-85711-084-8.

^ Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME,  et al. (December 2016). "Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis". The New England Journal of Medicine. 375 (26): 2519–29. doi:10.1056/NEJMoa1611593. PMID 27959716.

^ Jump up to: a b Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM,  et al. (January 2011). "Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis". BMJ. 342: c7086. doi:10.1136/bmj.c7086. PMC 3019238. PMID 21224324. c7086.

^ Jump up to: a b Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA,  et al. (August 2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390.

^ Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (May 2011). "Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans". Proceedings of the National Academy of Sciences of the United States of America. 108 (22): 9262–7. Bibcode:2011PNAS..108.9262W. doi:10.1073/pnas.1104836108. PMC 3107316. PMID 21518864.

^ Jump up to: a b Turner MS, May DB, Arthur RR, Xiong GL (March 2007). "Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks". Journal of Internal Medicine. 261 (3): 205–13. doi:10.1111/j.1365-2796.2006.01720.x. PMID 17305643. S2CID 41772614.

^ Jump up to: a b Pfau PR, Lichenstein GR (November 1999). "NSAIDs and alcohol: never the twain shall mix?". The American Journal of Gastroenterology. 94 (11): 3098–101. PMID 10566697.

^ Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA,  et al. (November 2010). "Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen". The Journal of Biological Chemistry. 285 (45): 34950–9. doi:10.1074/jbc.M110.162982. PMC 2966109. PMID 20810665.

^ Hinz B, Cheremina O, Besz D, Zlotnick S, Brune K (April 2008). "Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers". International Journal of Clinical Pharmacology and Therapeutics. 46 (4): 180–6. doi:10.5414/CPP46180. PMID 18397691.

^ Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W,  et al. (October 2000). "Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers". Journal of Clinical Pharmacology. 40 (10): 1109–20. doi:10.1177/009127000004001005 (inactive 31 October 2021). PMID 11028250.{{cite journal}}:  CS1 maint: DOI inactive as of October 2021 (link)

^ Gross GJ, Moore J (July 2004). "Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine". Pharmacology. 71 (3): 135–42. doi:10.1159/000077447. PMID 15161995. S2CID 34018223.

^ Hawkey CJ (October 2001). "COX-1 and COX-2 inhibitors". Best Practice & Research. Clinical Gastroenterology. 15 (5): 801–20. doi:10.1053/bega.2001.0236. PMID 11566042.

^ Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, Vree JB, Guelen PJ (August 1993). "Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans". Biopharmaceutics & Drug Disposition. 14 (6): 491–502. doi:10.1002/bdd.2510140605. PMID 8218967. S2CID 35920001.

^ Jump up to: a b c d Rodrigues AD (November 2005). "Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?". Drug Metabolism and Disposition. 33 (11): 1567–75. doi:10.1124/dmd.105.006452. PMID 16118328. S2CID 5754183.

^ "CYP2C9". pharmgkb.org. PharmGKB. Retrieved 17 May 2017.

^ el Mouelhi M, Ruelius HW, Fenselau C, Dulik DM (1987). "Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen". Drug Metabolism and Disposition. 15 (6): 767–72. PMID 2893700.

^ Harrington PJ, Lodewijk E (1997). "Twenty Years of Naproxen Technology". Org. Process Res. Dev. 1 (1): 72–76. doi:10.1021/op960009e.

^ "Vimovo- naproxen and esomeprazole magnesium tablet, delayed release". DailyMed. 2 August 2019. Retrieved 27 December 2019.

^ "Aleve- naproxen sodium tablet". DailyMed. 4 November 2019. Retrieved 27 December 2019.

^ "Medicines regulator approves availability of a new OTC medicine for period pain" (Press release). Medicines and Healthcare products Regulatory Agency (MHRA). 1 April 2008. Archived from the original (PDF) on 21 September 2013.

^ "Aleve products released in Canada".{{cite web}}:  CS1 maint: url-status (link)

^ "Aleve – Welcome to Canada, Eh!" (PDF) (Press release). Bayer Health Care. 14 July 2009. Retrieved 24 March 2012.

^ "Aleve – Helping British Columbians with Joint and Arthritis Pain Get Back to Doing the Activities They Love". newswire.ca. 28 January 2010.

^ Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B,  et al. (May 2013). "Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus". Antimicrobial Agents and Chemotherapy. 57 (5): 2231–42. doi:10.1128/AAC.02335-12. PMC 3632891. PMID 23459490. Lay summary – EurekAlert!. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)

^ McIlwraith CW, Frisbie DD, Kawcak CE (2001). "Nonsteroidal Anti-Inflammatory Drugs". Proceedings of the Annual Convention of the American Association of Equine Practitioners. 47: 182–187. ISSN 0065-7182.

^ May SA, Lees P (1996). "Nonsteroidal anti-inflammatory drugs".  In McIlwraith CW, Trotter GW (eds.). Joint disease in the horse. Philadelphia: WB Saunders. pp. 223–237. ISBN 0-7216-5135-6.


External links[edit]



Look up naproxen in Wiktionary, the free dictionary.

"Naproxen". Drug Information Portal. U.S. National Library of Medicine.
"Naproxen sodium". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteNonsteroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)Pyrazolones / Pyrazolidines
Aminophenazone
Ampyrone
Azapropazone
Clofezone
Difenamizole
Famprofazone
Feprazone
Kebuzone
Metamizole
Mofebutazone
Morazone
Nifenazone
Oxyphenbutazone
Phenazone
Phenylbutazone
Propyphenazone
Sulfinpyrazone
Suxibuzone‡
Salicylates
Aspirin (acetylsalicylic acid)#
Aloxiprin
Benorylate
Carbasalate calcium
Diflunisal
Dipyrocetyl
Ethenzamide
Guacetisal
Magnesium salicylate
Methyl salicylate
Salsalate
Salicin
Salicylamide
Salicylic acid (salicylate)
Sodium salicylate
Acetic acid derivativesand related substances
Aceclofenac
Acemetacin
Alclofenac
Amfenac
Bendazac
Bromfenac
Bumadizone
Bufexamac
Diclofenac
Difenpiramide
Etodolac
Felbinac
Fenclozic acid
Fentiazac
Indometacin
Indometacin farnesil
Isoxepac
Ketorolac
Lonazolac
Mofezolac
Oxametacin
Prodolic acid
Proglumetacin
Sulindac
Tiopinac
Tolmetin
Zomepirac†
Oxicams
Ampiroxicam
Droxicam
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Propionic acid derivatives(profens)
Alminoprofen
Benoxaprofen†
Carprofen‡
Dexibuprofen
Dexketoprofen
Fenbufen
Fenoprofen
Flunoxaprofen
Flurbiprofen
Ibuprofen#
Ibuproxam
Indoprofen†
Ketoprofen
Loxoprofen
Miroprofen
Naproxen
Oxaprozin
Piketoprofen
Pirprofen
Suprofen
Tarenflurbil
Tepoxalin‡
Tiaprofenic acid
Vedaprofen‡
Zaltoprofen
COX-inhibiting nitric oxide donator: Naproxcinod
N-Arylanthranilic acids(fenamates)
Azapropazone
Clonixin
Etofenamate
Floctafenine
Flufenamic acid
Flunixin
Glafenine†
Meclofenamic acid
Mefenamic acid
Morniflumate
Niflumic acid
Tolfenamic acid
Flutiazin
Coxibs
Apricoxib
Celecoxib (+tramadol)
Cimicoxib‡
Deracoxib‡
Etoricoxib
Firocoxib‡
Lumiracoxib†
Mavacoxib‡
Parecoxib
Robenacoxib‡
Rofecoxib†
Valdecoxib†
Other
Aminopropionitrile
Benzydamine
Chondroitin sulfate
Diacerein
Fluproquazone
Glucosamine
Glycosaminoglycan
Hyperforin
Nabumetone
Nimesulide
Oxaceprol
Proquazone
Superoxide dismutase/Orgotein
Tenidap
Combinations
Ibuprofen/famotidine
Ibuprofen/hydrocodone
Ibuprofen/oxycodone
Ibuprofen/paracetamol
Meloxicam/bupivacaine
Naproxen/diphenhydramine
Naproxen/esomeprazole
Items listed in underline indicate initially developed compounds of specific groups. #WHO-EM †Withdrawn drugs. ‡Veterinary use medications.
vteTopical products for joint and muscular pain (M02)Anti-inflammatory preparations, non-steroidsPyrazolidines
Clofezone
Mofebutazone
Oxyphenbutazone
Phenylbutazone
Acetic acid derivatives
Diclofenac
Fentiazac
Tolmetin
Other
Bendazac
Benzydamine
Bufexamac
Etofenamate
Felbinac
Feprazone
Flurbiprofen
Ibuprofen
Indometacin
Ketoprofen
Meclofenamic acid
Naproxen
Nifenazone
Niflumic acid
Piketoprofen
Piroxicam
Suxibuzone
Capsaicin derivatives
Zucapsaicin
Other
Dimethyl sulfoxide
Idrocilamide
Tolazoline

vteAnalgesics (N02A, N02B)OpioidsOpiates/opium
Codeine#
+aspirin
+paracetamol
Morphine# (+naltrexone)
Opium
Laudanum
Paregoric
Semisynthetic
Acetyldihydrocodeine
Benzylmorphine
Buprenorphine (+naloxone)
Butorphanol
Desomorphine
Diamorphine (heroin)
Dihydrocodeine (+paracetamol)
Dihydromorphine
Etorphine
Ethylmorphine
Hydrocodone (+paracetamol, +ibuprofen, +aspirin)
Hydromorphinol
Hydromorphone
Levorphanol
Metopon
Nalbuphine
Nicocodeine
Nicodicodine
Nicomorphine
Oxycodone (+paracetamol, +aspirin, +ibuprofen, +naloxone, +naltrexone)
Oxymorphone
Papaveretum
Thebacon
Synthetic
Alfentanil
Alphaprodine
Anileridine
Bezitramide
Carfentanil
Dextromoramide
Dextropropoxyphene
Dezocine
Dimenoxadol
Dipipanone
Ethoheptazine
Fentanyl# (+fluanisone)
Ketobemidone
Lofentanil
Meptazinol
Methadone#
NFEPP
Norpipanone
Oliceridine
Pentazocine
Pethidine (meperidine)
Phenadoxone
Phenazocine
Phenoperidine
Piminodine
Piritramide
Proheptazine
Propiram
Remifentanil
Sufentanil
Tapentadol
Tilidine
Tramadol
Viminol
Paracetamol-type
Acetanilide‡
Bucetin‡
Butacetin‡
Paracetamol (acetaminophen)#
+aspirin/caffeine
+codeine
+hydrocodone
+metoclopramide
+oxycodone
+propyphenazone/caffeine
Parapropamol‡
Phenacetin‡
Propacetamol‡
NSAIDsPropionates
Benoxaprofen ‡
Fenoprofen
Flurbiprofen
Ibuprofen# (Dexibuprofen)
Ketoprofen (Dexketoprofen)
Loxoprofen
Naproxen
Oxaprozin
Suprofen
Tiaprofenic acid
Zaltoprofen
Oxicams
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Acetates
Acemetacin
Bromfenac
Diclofenac
Etodolac
Indometacin (Indometacin farnesil)
Ketorolac
Sulindac
Tolmetin
Zomepirac ‡
COX-2 inhibitors
Celecoxib (+tramadol)
Etoricoxib
Lumiracoxib ‡
Parecoxib
Rofecoxib ‡
Valdecoxib ‡
Fenamates
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Tolfenamic acid
Salicylates
Aspirin (acetylsalicylic acid)# (+paracetamol/caffeine)
Aloxiprin
Benorylate
Carbasalate calcium
Choline salicylate
Diflunisal
Dipyrocetyl
Ethenzamide
Guacetisal
Imidazole salicylate
Magnesium salicylate
Morpholine salicylate
Potassium salicylate
Salicin
Salicylamide
Salsalate
Sodium salicylate
Wintergreen (methyl salicylate)
Pyrazolones
Aminophenazone‡
Ampyrone
Metamizole (dipyrone)
Nifenazone
Phenazone
Propyphenazone (+paracetamol/caffeine)
Others
Benzydamine
Floctafenine
Glafenine
Nabumetone
Nimesulide
Proquazone
Cannabinoids
Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)
Ion channelmodulatorsCalcium blockers
Alcohol (ethanol)
Gabapentin
Gabapentin enacarbil
Leconotide
Mirogabalin
Pregabalin
Ziconotide
Sodium blockers
Carbamazepine
Lacosamide
Local anesthetics (e.g., cocaine, lidocaine)
Mexiletine
Nefopam
Tricyclic antidepressants (e.g., amitriptyline#)
Nav1.7/1.8-selective: DSP-2230§
Funapide§
PF-05089771§
Potassium openers
Flupirtine‡
Myorelaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine
Others
Analgecine
Analgesic adjuvant
Bedinvetmab
Camphor
Capsaicin
Clonidine
Frunevetmab
Ketamine
Menthol
Methoxyflurane
Phenazopyridine
Proglumide
Rimazolium
Tanezumab

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteProlactin inhibitors and anti-inflammatory products for vaginal administration (G02CB–G02CC)Prolactin inhibitors
Bromocriptine
Cabergoline
Ergoloid
Lisuride
Metergoline
Pergolide
Quinagolide
Terguride
Anti-inflammatory productsfor vaginal administration
Benzydamine
Ibuprofen
Flunoxaprofen
Naproxen

vteProstanoid signaling modulatorsReceptor(ligands)DP (D2)DP1
Agonists: Prostaglandin D2
Treprostinil
Antagonists: Asapiprant
Laropiprant
Vidupiprant
DP2
Agonists: Indometacin
Prostaglandin D2
Antagonists: ADC-3680
AZD-1981
Bay U3405
Fevipiprant
MK-1029
MK-7246
QAV-680
Ramatroban
Setipiprant
Timapiprant
TM30089
Vidupiprant
EP (E2)EP1
Agonists: Beraprost
Enprostil
Iloprost (ciloprost)
Latanoprost
Lubiprostone
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Sulprostone
Antagonists: AH-6809
ONO-8130
SC-19220
SC-51089
SC-51322
EP2
Agonists: Butaprost
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Treprostinil
Antagonists: AH-6809
PF-04418948
TG 4-155
EP3
Agonists: Beraprost
Carbacyclin
Cicaprost
Enprostil
Iloprost (ciloprost)
Isocarbacyclin
Latanoprost
Misoprostol
Prostaglandin D2
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Remiprostol
Ricinoleic acid
Sulprostone
Antagonists: L-798106
EP4
Agonists: Lubiprostone
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
TCS-2510
Antagonists: Grapiprant
GW-627368
L-161982
ONO-AE3-208
Unsorted
Agonists: 16,16-Dimethyl Prostaglandin E2
Aganepag
Carboprost
Evatanepag
Gemeprost
Nocloprost
Omidenepag
Prostaglandin F2α (dinoprost)
Simenepag
Taprenepag
FP (F2α)
Agonists: Alfaprostol
Bimatoprost
Carboprost
Cloprostenol
Enprostil
Fluprostenol
Latanoprost
Prostaglandin D2
Prostaglandin F2α (dinoprost)
Sulotroban
Tafluprost
Travoprost
Unoprostone
IP (I2)
Agonists: ACT-333679
AFP-07
Beraprost
BMY-45778
Carbacyclin
Cicaprost
Iloprost (ciloprost)
Isocarbacyclin
MRE-269
NS-304
Prostacyclin (prostaglandin I2, epoprostenol)
Prostaglandin E1 (alprostadil)
Ralinepag
Selexipag
Taprostene
TRA-418
Treprostinil
Antagonists: RO1138452
TP (TXA2)
Agonists: Carbocyclic thromboxane A2
I-BOP
Thromboxane A2
U-46619
Vapiprost
Antagonists: 12-HETE
13-APA
AA-2414
Argatroban
Bay U3405
BMS-180,291
Daltroban
Domitroban
EP-045
GR-32191
ICI-185282
ICI-192605
Ifetroban
Imitrodast
L-655240
L-670596
Linotroban
Mipitroban
ONO-3708
ONO-11120
Picotamide
Pinane thromboxane A2
Ramatroban
Ridogrel
S-145
Samixogrel
Seratrodast
SQ-28,668
SQ-29,548
Sulotroban
Terbogrel
Terutroban
TRA-418
Unsorted
Arbaprostil
Ataprost
Ciprostene
Clinprost
Cobiprostone
Delprostenate
Deprostil
Dimoxaprost
Doxaprost
Ecraprost
Eganoprost
Enisoprost
Eptaloprost
Esuberaprost
Etiproston
Fenprostalene
Flunoprost
Froxiprost
Lanproston
Limaprost
Luprostiol
Meteneprost
Mexiprostil
Naxaprostene
Nileprost
Nocloprost
Ornoprostil
Oxoprostol
Penprostene
Pimilprost
Piriprost
Posaraprost
Prostalene
Rioprostil
Rivenprost
Rosaprostol
Spiriprostil
Tiaprost
Tilsuprost
Tiprostanide
Trimoprostil
Viprostol
Enzyme(inhibitors)COX(PTGS)
Salicylic acids: Aloxiprin
Aspirin (acetylsalicylic acid)
Benorilate (benorylate)
Carbasalate calcium
Diflusinal
Dipyrocetyl
Ethenzamide
Guacetisal
Magnesium salicylate
Mesalazine (5-aminosalicylic acid)
Methyl salicylate
Salacetamide
Salicin
Salicylamide
Salicylate (salicylic acid)
Salsalate
Sodium salicylate
Triflusal; Acetic acids: Aceclofenac
Acemetacin
Aclofenac
Amfenac
Alclofenac
Bendazac
Bromfenac
Bufexamac
Bumadizone
Cinmetacin
Clometacin
Diclofenac
Difenpiramide
Etodolac
Felbinac
Fenclofenac
Fentiazac
Glucametacin
Indometacin (indomethacin)
Indometacin farnesil
Ketorolac
Lonazolac
Mofezolac
Nabumetone
Oxametacin
Oxindanac
Proglumetacin
Sulindac
Sulindac sulfide
Tolmetin
Zidometacin
Zomepirac; Propionic acids: Alminoprofen
Benoxaprofen
Bucloxic acid (blucloxate)
Butibufen
Carprofen
Dexibuprofen
Dexindoprofen
Dexketoprofen
Fenbufen
Fenoprofen
Flunoxaprofen
Flurbiprofen
Ibuprofen
Ibuproxam
Indoprofen
Ketoprofen
Loxoprofen
Miroprofen
Naproxen
Naproxcinod
Oxaprozin
Pirprofen
Pranoprofen
Suprofen
Tarenflurbil
Tepoxalin
Tiaprofenic acid (tiaprofenate)
Vedaprofen; Anthranilic acids (fenamic acids): Etofenamic acid (etofenamate)
Floctafenic acid (floctafenate)
Flufenamic acid (flufenamate)
Meclofenamic acid (meclofenamate)
Mefenamic acid (mefenamate)
Morniflumic acid (morniflumate)
Niflumic acid (niflumate)
Talinflumic acid (talinflumate)
Tolfenamic acid (tolfenamate); Pyrazolones: Azapropazone
Dipyrone
Isopyrin
Oxyphenbutazone
Phenylbutazone; Enolic acids (oxicams): Ampiroxicam
Droxicam
Enolicam
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam; 4-Aminoquinolines: Antrafenine
Floctafenine
Glafenine; Quinazolines: Fluproquazone
Proquazone; Aminonicotinic acids: Clonixeril
Clonixin
Flunixin; Sulfonanilides: Flosulide
Nimesulide; Aminophenols (anilines): Acetanilide
AM-404 (N-arachidonoylaminophenol)
Bucetin
Paracetamol (acetaminophen)
Parapropamol
Phenacetin
Propacetamol; Selective COX-2 inhibitors (coxibs): Apricoxib
Celecoxib
Cimicoxib
Deracoxib
Etoricoxib
Firocoxib
Lumiracoxib
Mavacoxib
Parecoxib
Polmacoxib
Robenacoxib
Rofecoxib
Tilmacoxib
Valdecoxib; Others/unsorted: Anitrazafen
Clobuzarit
Curcumin
DuP-697
FK-3311
Flumizole
FR-122047
Glimepiride
Hyperforin
Itazigrel
L-655240
L-670596
Licofelone
Menatetrenone (vitamin K2)
NCX-466
NCX-4040
NS-398
Pamicogrel
Resveratrol
Romazarit
Rosmarinic acid
Rutecarpine
Satigrel
SC-236
SC-560
SC-58125
Tenidap
Tiflamizole
Timegadine
Trifenagrel
Tropesin
PGD2S
Retinoids
Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
PGESHQL-79PGFSBimatoprostPGI2STranylcypromineTXAS
Camonagrel
Dazmegrel
Dazoxiben
Furegrelate
Isbogrel
Midazogrel
Nafagrel
Nicogrelate
Ozagrel
Picotamide
Pirmagrel
Ridogrel
Rolafagrel
Samixogrel
Terbogrel
U63557A
Others
Precursors: Linoleic acid
γ-Linolenic acid (gamolenic acid)
Dihomo-γ-linolenic acid
Diacylglycerol
Arachidonic acid
Prostaglandin G2
Prostaglandin H2

See also
Receptor/signaling modulators
Leukotriene signaling modulators

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





